Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) EBIT (2018 - 2025)

Viemed Healthcare's EBIT history spans 8 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, EBIT rose 29.74% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $22.9 million, up 28.21%, while the annual FY2025 figure was $22.9 million, 28.21% up from the prior year.
  • EBIT reached $8.4 million in Q4 2025 per VMD's latest filing, up from $5.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.4 million in Q4 2025 to a low of $1.0 million in Q2 2022.
  • Average EBIT over 5 years is $3.8 million, with a median of $3.6 million recorded in 2022.
  • Peak YoY movement for EBIT: plummeted 79.28% in 2021, then soared 189.81% in 2023.
  • A 5-year view of EBIT shows it stood at $4.7 million in 2021, then decreased by 24.24% to $3.5 million in 2022, then surged by 49.66% to $5.3 million in 2023, then rose by 21.99% to $6.5 million in 2024, then increased by 29.74% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for VMD's EBIT are $8.4 million (Q4 2025), $5.6 million (Q3 2025), and $5.1 million (Q2 2025).